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Summary
Angioblasts are multipotent progenitor cells that give
rise to arteries or veins [1]. Genetic disruption of the
gridlock gene perturbs the artery/vein balance, result-
ing in generation of insufficient numbers of arterial
cells [2]. However, within angioblasts the precise bio-
chemical signals that determine the artery/vein cell-
fate decision are poorly understood. We have identi-
fied by chemical screening two classes of compounds
that compensate for a mutation in the gridlock gene
[3]. Both target the VEGF signaling pathway and reveal
two downstream branches emanating from the VEGF
receptor with opposing effects on arterial specifica-
tion. We show that activation of ERK (p42/44 MAP ki-
nase) is a specific marker of early arterial progenitors
and is among the earliest known determinants of arte-
rial specification. In embryos, cells fated to contribute
to arteries express high levels of activated ERK,
whereas cells fated to contribute to veins do not. Inhib-
iting the phosphatidylinositol-3 kinase (PI3K) branch
with GS4898 or known PI3K inhibitors, or by expres-
sion of a dominant-negative form of AKT promotes ar-
terial specification. Conversely, inhibition of the ERK
branch blocks arterial specification, and expression
of constitutively active AKT promotes venous specifi-
cation. In summary, chemical genetic analysis has
uncovered unanticipated opposing roles of PI3K and
ERK in artery/vein specification.
Results and Discussion
How arterial and venous cells arise from common angio-
blast progenitors to form a functional vasculature poses
a challenging biological question. Artery versus vein
(A/V) specification is established prior to the onset of
circulation [2, 4, 5], and once specified, arterial and ve-
nous progenitors migrate to the appropriate locales
and coalesce into functional vessels. The transcriptional
repressor hey2, encoded by the gridlock gene in zebra-
fish, is an important determinant of the arterial fate, as
evidenced by the fact that disruption of gridlock results
in formation of insufficient numbers of arterial cells
that leads to reduction or loss of the aorta [2, 6].
*Correspondence: peterson@cvrc.mgh.harvard.eduConsequently, zebrafish with a mutation (grlm145) in
hey2/gridlock lack trunk and tail circulation because of
an aortic dysmorphogenesis that resembles congenital
aortic coarctation in humans (Figure 1A) [7]. In the
mouse, defects in the hey2 gene contribute to vascular
deformities as well [8, 9]. Beyond gridlock, other genetic
and biochemical factors are likely involved in A/V spec-
ification [10]. Identifying additional factors via traditional
genetic approaches may be difficult, particularly if such
factors are necessary for vital biological processes that
occur prior to formation of the vasculature. For the iden-
tification of novel factors that govern the artery/vein cell-
fate decision, it will be important to employ a strategy
that enables control over the dose and timing of gene
inactivation. Therefore, instead of traditional genetic ap-
proaches, we have employed small-molecule screening
to identify conditional modifiers of the artery/vein cell-
fate decision.
Previously, chemical screening was performed with
whole zebrafish embryos, and a small molecule,
GS4012, was identified that suppresses the vascular
defect in gridlock mutant embryos [3]. GS4012 was pos-
tulated to function via activation of the VEGF signaling
pathway. We have used a similar screening approach
to identify a distinct compound class that is also capable
of suppressing the gridlock phenotype (Figure 1A). These
compounds, represented by the compound GS4898,
possess a mechanism of action that is distinct from
that of GS4012. We have used these two classes of grid-
lock suppressors to reveal the biochemical basis for
artery/vein specification during embryogenesis.
GS4898, which is structurally distinct from GS4012
(Figure 1B), was identified in a screen of 7000 uncharac-
terized small molecules on the basis of its ability to re-
store trunk and tail circulation to zebrafish embryos
that are homozygous gridlock (grlm145) mutants. GS4898
is a flavone structurally similar to several small-molecule
inhibitors of protein kinases [11, 12], suggesting that
GS4898 might function by targeting a kinase. We tested
structurally related flavone kinase inhibitors and found
that LY294002, a specific phosphatidylinositol-3 kinase
(PI3K) inhibitor, is also capable of suppressing the grid-
lock phenotype (Figure 1B). In addition, the structurally
unrelated PI3K inhibitor wortmannin suppresses the
gridlock phenotype. Moreover, GS4898 inhibits activa-
tion of AKT, a downstream mediator of PI3K signaling
[13], in whole zebrafish embryos (Figure 1C). These
data strongly suggest that PI3K inhibition underlies the
suppression of the gridlock phenotype by GS4898.
GS4898 is capable of suppressing the gridlock pheno-
type in the 1–5 mM range (Figure 1D). At higher doses,
GS4898, LY294002, and wortmannin each causes se-
vere vascular defects. As discussed below, such high
doses may cause severe perturbations in angioblast
cell-fate determination as a result of a complete inhibi-
tion of PI3K. Thus, suppression of the gridlock pheno-
type by GS4898 appears to require a partial inhibition
of PI3K, sufficient to overcome deficient arterial cell
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1367Figure 1. Suppression of the gridlock Phenotype by the Novel Flavone GS4898 Involves PI-3 Kinase Inhibition
(A) Suppression of the gridlock phenotype (atresia of the proximal aorta in grlm145 mutants) by GS4898 [2-(4-methylphenyl)-4H-chromen-4-one].
Above, a microangiogram of an untreated 60 hpfgrlm145 mutant, in which arterial circulation to the tail is disrupted, is shown. Below, a microangio-
gram shows the restoration of tail circulation in a grlm145 mutant by GS4898 treatment.
(B) The gridlock phenotype is suppressed by GS4012, GS4898, LY294002, and wortmannin, but not PD98059 and quercetin. GS4898 and the
PI3K inhibitors are enclosed in dashed boxes.
(C) Quantitative western analysis of activating AKT phosphorylation (at Ser472) in 20-somite-stage (ss) zebrafish embryos shows dramatic
reduction in AKT phosphorylation by GS4898 (25 mM) or wortmannin (0.5 mM) treatment, starting at 10 hpf. Results were normalized from three
independent experiments and achieved significance at p < 0.004 for each condition versus untreated. Error bars represent standard error.
(D) Dose response for GS4898, LY294002, and wortmannin. Compounds were added at 12 hpf and washed out at 27 hpf. Suppression (%)
represents percentage of treated embryos that have tail circulation at 48 hpf. Number on top of each bar represents actual number of embryos
with normal tail flow over the total number treated.
(E) Model for two VEGF-receptor-dependent signaling branches with opposing effects on arterial specification. The PLC-g/ERK branch mediates
arterial cell specification, whereas the PI3K branch exerts a negative effect on the PLC-g/ERK branch, possibly via direct inhibition of Raf by Akt.
By blocking PI3K, GS4898 lifts PI3K’s inhibition of the PLC-g/ERK pathway, leading to increased ERK activation and arterial specification.
(F) Synergy between GS4898 or PI3K inhibitors and GS4012. Single treatment involving a subeffective dose of GS4898 (0.75 mM), LY294002
(3 mM), wortmannin (0.075 mM), or GS4012 (0.7 mg/mL) does not suppress the gridlock phenotype, but cotreatment with GS4012 and GS4898,
LY294002, or wortmannin at the same doses leads to significant suppression of the gridlock phenotype.formation but not sufficient to grossly distort the artery/
vein balance.
Suppression of the gridlock vascular defect by inhibi-
tion of PI3K, a well-known mediator of VEGF signaling, is
intriguing because GS4012 was postulated to act via
activation of the VEGF signaling pathway and VEGF
cDNA injection can suppress the gridlock phenotype
[3]. This apparent paradox led us to consider a hypothe-
sis in which one of the two best-characterized branches
of VEGF signaling [13], namely the PLC-g/MAP kinase
(ERK) pathway, triggers arterial fate specification,
whereas the other, the PI3K/Akt branch, exerts an inhib-
itory effect on the PLC-g/ERK branch (Figure 1E) [14].
Evidence for such crosstalk between the two signaling
pathways has been observed at the level of directphosphorylation of Raf by Akt in a human cancer cell
line [15]. This model is attractive because PLC-g is
known to be required specifically for artery, but not
vein, development in the zebrafish [16]. In this model,
GS4898 compensates for the deficient artery formation
in gridlock mutants by lifting PI3K’s inhibition of the ar-
teriogenic PLC-g/ERK branch (Figure 1E). If this model
is correct, GS4898 and the PI3K inhibitors LY294002
and wortmannin would be predicted to potentiate the
effects of the putative VEGF pathway activator GS4012.
Indeed, we find that GS4898, LY294002, and wortman-
nin synergize with GS4012 in suppressing the gridlock
phenotype (Figure 1F). Moreover, GS4898 or LY294002
treatment significantly increases activation of ERK, a
central downstream mediator of PLC-g [13], in whole
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1368Figure 2. Diphosphorylated ERK Is a Specific
Marker of Early Arterial Progenitors
(A–C) Immunostain for activated (diphos-
phorylated) ERK in 20-ss zebrafish embryos.
Arrowhead shows activated ERK within the
developing vasculature. In (B), dorsal side is
to the right, and in (C) and in all other cross-
sections, dorsal is to the top. NC denotes no-
tochord, which lies dorsal to the angioblasts.
(D–F) Cross-sections of immunostain for acti-
vated ERK in 12-ss (15 hpf) embryos (D and E)
and in a 24 hpf embryo (F). (E) shows a
merged view of angioblasts, marked by GFP
(green) expressed under the fli-1 vascular-
specific promoter [26] and by activated ERK
(yellow). At around 12 ss, activated ERK
(yellow) is preferentially detectable in angio-
blasts that reach the midline earlier than the
rest of the angioblasts (green). (F) By around
24 hpf, activated ERK is no longer detected
in angioblasts.
(G–I) Cross-section of a 20-ss embryo. (G)
shows angioblasts marked by vascular-spe-
cific GFP (green). (H) shows immunostain
for activated ERK (red). (I) Merged view of ac-
tivated ERK and GFP, with overlap in yellow.
At this stage, detectable ERK activation is
restricted to the dorsal-most angioblasts
(yellow).
(J and M) Quantitative western analysis of
ERK phosphorylation in 20-ss embryos. Error
bars represent standard error. (J) Inhibition of
ERK phosphorylation by cyclopamine (50 mM)
or 676475 (25 mg/mL) treatment, starting at
10 hpf. Results were normalized from three
independent experiments and achieved sig-
nificance at p = 0.03 for cyclopamine and
p < 0.0001 for 676475 versus untreated. (M)
shows enhancement of ERK phosphorylation
by GS4898 (10 mM) or LY294002 (15 mM) treat-
ment, starting at 10 hpf. Results were normal-
ized from seven independent experiments
and achieved significance at p = 0.04 for
GS4898 and p = 0.009 for LY294002 versus
untreated.
(K and L) Merged view of activated ERK and
GFP in embryos treated with cyclopamine
(K) or 676475 (L). Note the loss of ERK activa-
tion with cyclopamine and 676475 treat-
ments.
(N and O) Merged view of activated ERK and
GFP in embryos treated with GS4898 (N) and
LY294002 (O) showing the relative expansion
in the overlap (yellow) between angioblasts
and activated ERK.embryos (Figure 2M). These data support a hypothesis
in which GS4898 promotes arterial specification by lift-
ing PI3K’s inhibition of ERK signaling (Figure 1E).
The possible involvement of ERK signaling in arterial
cell-fate specification led us to consider whether it might
be activated specifically in the prearterial subpopulation
of angioblasts. Using an antibody specific for ERK acti-
vated by dual phosphorylation at Thr-202 and Tyr-204
[15, 17], we found that activated ERK (dp-ERK) is prefer-
entially localized to endothelial precursors fated to be-
come arterial cells during a critical period invasculogenesis (Figures 2A–2I). Starting around 15 hr
postfertilization (hpf), activated ERK is detected in a sub-
set of angioblasts that migrate from their origin in the lat-
eral mesoderm toward the midline (Figures 2D and 2E).
This pattern of activated ERK detected in the migrating
angioblasts is reminiscent of the ERK activation in the
migrating lateral tracheal branches in Drosophila [18].
Most remarkably, ERK activation persists in the dor-
sal-most angioblasts, adjacent to the notochord (Fig-
ures 2H and 2I), but not in ventral angioblasts. By
17 hpf, these dorsal-most angioblasts express the
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rial endothelial cells of the aorta, which invariably forms
dorsally in relation to the posterior cardinal vein [19]. By
24 hpf, activated ERK becomes undetectable in
endothelial cells as the aorta matures (Figure 2F). The
exquisite patterns of ERK activation in the arterial pro-
genitors and the newly differentiated arterial endothelial
cells raise the intriguing possibility that ERK activation is
an early marker and/or determinant of the arterial cell
fate [20].
If ERK activation is an arterial cell-fate marker, disrup-
tion of arterial specification should lead to perturbations
in ERK activation. In the zebrafish embryo, two extra-
cellular signals, sonic hedgehog (shh) and VEGF, ex-
pressed in the notochord and somites, respectively,
are required for arterial specification [10, 21]. We found
that blocking arterial formation with the hedgehog path-
way inhibitor cyclopamine or the VEGF receptor (types 1
and 2) inhibitor 676475 greatly reduces ERK phosphory-
lation on quantitative western analysis of whole-embryo
lysates and causes a loss of ERK activation within endo-
thelial cells on whole-mount embryo immunostaining
(Figures 2J–2L). Interestingly, treatment with GS4898
or LY294002 not only increases ERK activation on quan-
titative western analysis, but also causes an expansion
of ERK activation within the endothelial cell population
(Figures 2N and 2O). These data demonstrate that ERK
activation is indeed an early marker of the arterial cell
fate [20]. In addition, they suggest that PI3K may func-
tion to spatially limit ERK activation to the dorsal-most
endothelial cells.
If ERK activation within a specific subset of angio-
blasts is a determinant of the arterial fate, changes in
ERK activation should lead to perturbations in artery/
vein specification. Indeed, we find that augmenting
ERK activation increases artery and decreases vein for-
mation. For example, treatment with GS4898 leads to
occasional duplication of the aorta (Figure 3E and Fig-
ure 3G, middle) and to either loss or reduction of venous
structures, such as the common cardinal vein (Figures
3C and 3E and Figure 3G, middle). In contrast, blocking
ERK activation decreases artery and increases vein
formation. For example, treatment with either SL327 or
U0126, inhibitors of MEK, an upstream activator of
ERK, leads to either loss or reduction of the aorta (Fig-
ures 3C and 3F and Figure 3G, right) and to an expansion
of the common cardinal vein (Figure 3F and Figure 3G,
right). In summary, stimulation of ERK activation shifts
the artery/vein decision in favor of artery formation,
whereas inhibition of ERK has the opposite effect.
Therefore, activation of ERK in angioblasts is a key
determinant of arterial specification.
Our findings from a chemical genetic approach indi-
cate that PI3K and ERK have surprisingly opposing roles
in artery/vein specification. Because PI3K and ERK are
ubiquitously expressed signaling molecules utilized
multiple times during embryonic development, tradi-
tional genetic disruptions of these pathways result in
gross perturbation of the dorsoventral axial pattern
[22] and in abnormal morphogenetic movements during
gastrulation [23]. Nevertheless, mild defects such as de-
ficient intersomitic vessel formation caused by a tran-
sient treatment with a VEGF inhibitor could be partially
reversed by a low-dose injection of mRNA encodingconstitutively active AKT [24]. In contrast, our attempts
to overexpress constitutively active or dominant-nega-
tive forms of ERK, MEK, or AKT in embryos have re-
sulted in early embryonic deaths that preclude an
adequate assessment of their effects on artery/vein
specification (unpublished data). These results highlight
an inherent advantage of using small molecules for dis-
section of vascular development, because limiting com-
pound exposure to critical times in vasculogenesis al-
lows a relatively targeted perturbation of artery/vein
specification while minimizing gross embryonic defects
or lethality associated with complete disruption of pleio-
tropic factors (see the Supplemental Data available
online).
To overcome the early-lethal effects of globally per-
turbing PI3K, we used mosaic expression of a domi-
nant-negative form of AKT (DN-AKT) by injecting into
1- to 2-cell-stage embryos the expression plasmid pAd-
TrackCMV.AA-AKT, which expresses both GFP and
DN-AKT under separate CMV promoters [25]. Mosaic
coexpression of constitutively active, myristoylated
AKT (myr-AKT) and GFP was also achieved with a similar
strategy. A low-dose (50 pg) injection, which permitted
grossly normal development and establishment of cir-
culation, resulted in a very small fraction (<1%) of cells
that express GFP (Figure 4A). If inhibition of PI3K/AKT
signaling in angioblasts promotes arterial specification,
the rare angioblasts that express the dominant-negative
AKT in such a mosaic setting would be predicted to be-
come arterial endothelial cells. Conversely, if activation
of PI3K/AKT signaling in angioblasts promotes venous
specification, angioblasts that express myr-AKT would
be predicted to become venous endothelial cells. In-
deed, a blinded analysis of these GFP-positive cells
localizing to either the dorsal aorta (Figure 4B) or the
axial vein (Figure 4C) indicates that GFP-positive cells
are preferentially found in the dorsal aorta when
injected with the construct coexpressing DN-AKT (pAd-
TrackCMV.AA-AKT), whereas GFP-positive cells are
preferentially found in the vein when injected with the
construct coexpressing myr-AKT (pAdTrackCMV.myr-
AKT) (Figure 4D). These results provide further support
for the model in which PI3K/AKT signaling in angioblasts
functions to block ERK-mediated arterial specification
(Figure 1E).
Conclusions
The two compound classes identified by unbiased
screening in mutant zebrafish have been valuable tools
for studying artery/vein specification. Not only have
they confirmed the importance of VEGF signaling in
this process, but they have also revealed that two down-
stream components of VEGF signaling surprisingly have
opposite effects on artery/vein specification of endothe-
lial progenitor cells. ERK signaling promotes the arterial
cell fate, whereas PI3Kinase has an opposing effect by
blocking ERK activation. GS4898 and known PI3K inhib-
itors shift the artery/vein balance in favor of arterial de-
velopment. We note with interest that suppression of
the gridlock vascular defect by GS4898 likely involves
a partial inhibition of PI3K sufficient to overcome defi-
cient arterial cell formation but not sufficient to grossly
disrupt artery/vein balance. In light of this, it is doubtful
that a typical loss-of-function genetic lesion in PI3K
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(A) A 30 hpf embryo. Red line indicates dorsal aorta (DA). Blue line indicates posterior cardinal vein (PCV), which terminates at the common car-
dinal vein (CCV). Yellow box indicates the region shown in (B). Green vertical line indicates cross-sections in (C)–(F).
(B) In situ hybridization of 30 hpf embryos with the arterial marker ephrin-B2a. At left, normal ephrin-B2a expression (arrowhead) in untreated
embryos is shown. In the middle, intact ephrin-B2a expression in an embryo treated with high-dose (15 mM) GS4898 is shown. At right, eph-
rin-B2a expression is lost in SL327-treated (60 mM) embryos.
(C) Cross-sections of embryos shown in (B). At left, in untreated embryos, ephrin-B2a is expressed in the DA (black arrowhead), but not in the
PCV (white arrowhead). In the middle, in GS4898-treated embryos, the ephrin-B2a expressing DA is prominent, but the PCV is not visible. At right,
in SL327-treated embryos, neither ephrin-B2a expression nor the DA is observed.
(D–F) Cross-sections of 48 hpf embryos immunostained for GFP (brown) expressed in endothelial cells under the vascular-specific fli-1 pro-
moter. Arrowheads indicate the aorta. (D) In untreated embryos, both the dorsal aorta (A) and the posterior cardinal vein (V) are prominent.
(E) In embryos treated with 15 mM GS4898, duplication of the aorta is observed. (F) In embryos treated with 100 mM U0126, the aorta is greatly
reduced, whereas the vein (V) is enlarged. (G) At top, fluorescent images of 48 hpf embryos expressing GFP in endothelial cells are shown. Dorsal
view of the torso at the DA bifurcation and the PCV terminating at the CCV is shown. The head is above, and the tail is below. At bottom, cartoon
representations of the fluorescent images are shown. At left, in untreated embryos, the CCV, via which blood from the tail drains to the heart, is
situated lateral to the DA, which delivers blood to the tail. At the levels of the lower trunk and tail, the DA is situated dorsal to the PCV. In the
middle, in GS4898-treated embryos, the DA is partially duplicated, and the CCV, situated lateral to the DA, is greatly reduced. At right, in
SL327-treated embryos, the DA is missing and the CCV is significantly enlarged.signaling could have suppressed the gridlock pheno-
type. Furthermore, the use of chemical suppressors
allowed focused analysis of the role of PI3K and ERK
in artery/vein specification, despite their pleiotropic re-
quirement during early development [22, 23]. In summary,the chemical genetic approach employed here was in-
strumental in the discovery of previously unsuspected
roles of two well-known VEGF signaling branches, dem-
onstrating the utility and power of chemical genetics in
the study of vertebrate development.
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1371Figure 4. Genetic Manipulation of AKT Activ-
ity Influences Artery/Vein Specification
(A–C) Overlay of GFP-fluorescence image
onto bright-field image of a live 48 hp embryo
injected with pAdTrackCMV.AA-AKT (domi-
nant-negative AKT), pAdTrackCMV.myr-AKT
(myristoylated AKT), or pAdTrackCMV (GFP
alone). (A) Tail region of a plasmid-injected
embryo expressing GFP in a small subset of
cells is shown. Yellow box indicates the re-
gion represented in (B) and (C). (B) A high-
magnification overlay image of a typical
GFP-positive patch scored as arterial (red as-
terisk) is shown. It overlaps with the aorta (A),
with a robust arterial flow (red arrow). (C) An
overlay image of a typical GFP+ patch scored
as venous (blue asterisk) is shown. It overlaps
with the caudal vein, with a robust venous
flow.
(D) Numbers of GFP-positive patches in the
aorta and in the caudal vein in embryos
injected with pAdTrackCMV.AA-AKT (DN-
AKT), pAdTrackCMV.myr-AKT (myr-AKT),
and pAdTrackCMV (GFP alone). A significant
skewing of vascular GFP-positive cells in fa-
vor of aorta is noted in DN-AKT-injected em-
bryos (p = 0.028, versus GFP alone), whereas
a significant skewing of vascular GFP-posi-
tive cells in favor of vein is noted in myr-
AKT-injected embryos (p = 0.0039, versus
GFP alone).Experimental Procedures
Screening for Suppressors of the gridlock Phenotype
The screen was performed as previous described with modifications
[3]. Briefly, pairs of homozygous grlm145 zebrafish were mated, and
fertilized eggs were arrayed in 96-well plates containing E3 embryo
buffer. At the 6-somite stage, small molecules from the DiverSet E
library (Chembridge) were added to each well, yielding a final con-
centration of 2.5 mM. Embryos were incubated at 28.5ºC for 48 hr.
Circulation to the tail was assessed visually with a dissecting micro-
scope.
Fluorescent Microangiography
Fluorescence microangiography was performed as previously de-
scribed [7].
Quantitative Western Analysis
Control and treated 20 hr embryos were homogenized in SDS lysis
buffer. Denatured lysates from equivalent numbers of embryos (typ-
ically 7) were loaded and separated on a 10% SDS polyacrylamide
gel and transferred to a PVDF membrane. For Akt analyses, lysates
were prepared from equivalent deyolked embryos. Membranes
were blocked in 5% nonfat dry milk and incubated with rabbit poly-
clonal anti-phospho-p44/42 MAP kinase (Thr202/Tyr204), anti-p44/
42 MAP kinase, anti-phospho-Akt (Ser472), or anti-Akt (Cell Signal-
ing Technology). The membranes were then washed and incubated
with goat anti-rabbit horseradish peroxidase (HRP)-conjugatedsecondary antibodies. After several washes, membranes were de-
veloped with ECL+ chemiluminescence substrates and scanned
with a Typhoon Imager (Amersham). Band intensities were quanti-
fied with image quantification software. After each immunoblotting,
membranes were stripped according to manufacturer’s instructions
prior to incubation with other antibodies. For each membrane, the
ratio of phospho-MAP kinase to total MAP kinase was calculated.
The ratio between phospho-AKT and AKT was calculated in a similar
fashion. For comparison between individual experiments, ratios
were normalized to ratios obtained in control samples.
Immunostaining
Zebrafish embryos expressing EGFP under the fli-1 promoter [26]
were fixed in 4% paraformaldehyde and stored in methanol at
220ºC until needed. Embryos were rehydrated, blocked in 2%
sheep serum, and incubated with primary antibodies (rabbit poly-
clonal anti-phospho-p44/42 MAP kinase and mouse monoclonal
anti-GFP). After several washes in blocking solution, embryos
were incubated with secondary antibodies (goat anti-rabbit conju-
gated to either Alexa Fluor 594 or HRP, and goat anti-mouse conju-
gated to FITC, BD Biosciences). After extensive washes, embryos
were embedded in plastic (JB-4) and sectioned. Immunofluorescent
images of embryo sections were then analyzed with MetaMorph
image analysis software. For specimens incubated with secondary
antibody conjugated to HRP, color reaction was performed prior
to plastic embedment.
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Whole-mount RNA in situ hybridization for ephrin-B2 expression
was performed as described [2]. For sections, specimens were em-
bedded in JB-4 plastic after color reaction.
cDNA Injections and Identification of GFP-Positive
Cells within the Vasculature
Embryos were injected at the 1- to 2-cell stage with 1 nL of 50 mg/mL
pAdTrackCMV.AA-AKT plasmid encoding GFP and DN-AKT, pAd-
TrackCMV.myr-AKT plasmid encoding GFP and myr-AKT, or pAd-
TrackCMV containing only GFP. More than 200 embryos were
injected for each construct. Embryos were incubated at 28.5ºC for
48 hr, and surviving embryos with intact circulation were analyzed
for the presence of GFP-positive cells within the vasculature with
a fluorescent microscope by an observer blinded to the injected
plasmid. A GFP-positive cell was scored as arterial only if it lay im-
mediately adjacent to a strong arterial stream on the same focal
plane. Likewise, a GFP-positive cell was scored as venous if it lay
immediately adjacent to a strong venous stream on the same focal
plane. Because of frequent intense fluorescence of the yolk, analysis
was limited to the tail region caudal to the yolk extension.
Supplemental Data
Supplemental Data include one figure and are available with this
article online at: http://www.current-biology.com/cgi/content/full/
16/13/1366/DC1/.
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